Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
1. Clearmind begins Phase I/IIa trial for CMND-100 in AUD patients. 2. Trial at Johns Hopkins, Yale, and IMCA sites marks a milestone. 3. CMND-100 aims to reduce alcohol cravings, offering a novel treatment. 4. Alcohol Use Disorder affects millions, highlighting urgent treatment needs. 5. Study indicates growing recognition of CMND-100’s breakthrough potential.